Shots:

• Dr. Reddy’s to receive $40M up front upon the closing of the transaction- followed by ~$40M milestones on E7777’s approval in CTCL and ~$70M for additional indication approvals. Additionally- Dr. Reddy’s will receive commercial milestones and royalties
• Citius to get all the rights to E7777 (an engineered IL-2-diphtheria toxin fusion protein) and certain related assets
• Dr. Reddy’s had acquired the exclusive global rights (Ex-Japan and Asia) to the investigational anti-cancer agent- E7777 from Eisai in Mar’2016

  | Ref: Businesswire | Image: Dr. Reddy's